Treatment with the biosimilar, the investigators concluded, resulted in comparable, maintained quality of life improvements that were not impacted by a switch from the reference product.
Fresenius Kabi’s adalimumab biosimilar, approved in the European Union as Idacio, has demonstrated that it has similar pharmacokinetics, safety, and immunogenicity to its reference, Humira, in healthy volunteers as well as in patients with moderate to severe plaque psoriasis. In a study presented at the ISPOR 2019 meeting, researchers presented new data on the comparability of quality of life (QOL) improvements in patients treated with the biosimilar versus those treated with the reference.
In the double-blind, multicenter, 52-week phase 3 AURIEL-PsO study (for which data have been reported elsewhere, and which was included in Fresenius Kabi’s data package presented to the European Medicines Agency), patients were randomized to receive either the biosimilar or the reference. At week 16, patients who had a PASI 50 response were re-randomized to continue treatment or to switch to the biosimilar until week 52.
The per-protocol set included 203 patients receiving the biosimilar and 191 patients receiving the reference product. Patients’ QOL was assessed using the Dermatology Life Quality Index (DLQI) and EuroQol 5-dimension 5-level questionnaires (EQ-5D-5L). Among the 43 patients who also had psoriatic arthritis, the Health Assessment Questionnaire-Disability Index (HAQ-DI) and Psoriatic Arthritis Joint Activity-Visual Analog Scale (PJA-VAS) were also used.
Improvements from baseline to week 16 for all QOL scores were comparable, report the investigators. At week 16, the least squares mean differences for the biosimilar versus reference were as follows:
Improvements in QOL scores were maintained across treatment arms to week 52, including in the patients who switched from to the biosimilar at the week 16 switch.
Treatment with the biosimilar, the investigators concluded, resulted in comparable, maintained QOL improvements, and switching from the reference did not impact QOL.
Reference
Hercogová J, Papp KA, Chyrok V, et al. Quality-of-life outcomes comparing the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis. Presented at: International Society for Pharmacoeconomics and Outcomes Research 24th Annual International Meeting; May 18-22, 2019; New Orleans, Louisiana. Abstract PBI35.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
The 6 Key Policy Factors to Ensure Biosimilar Market Sustainability
April 16th 2024Magnus Bodin, senior director and head of international access and policy at Biogen, presented warning signs for unsustainable biosimilar markets as well as key factors needed to create effective policies and future-proof biosimilar markets globally.